[{"orgOrder":0,"company":"CinPhloro Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Phloroglucinol","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinPhloro Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinPhloro Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinPhloro Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Phloroglucinol Dihydrate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PODD Partnership
                          Not Confirmed
                          PODD Partnership
                          Not Confirmed

                          Details : CIN-103 (phloroglucinol) is a voltage-gated calcium channel blocker. It is being evaluated as a new approach for the chronic treatment of irritable bowel syndrome with predominant diarrhea (IBS-D).

                          Brand Name : CIN-103

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 22, 2024

                          Lead Product(s) : Phloroglucinol

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank